Alterity Therapeutics published a study in Annals of Clinical and Translational Neurology introducing the MSA Atrophy Index, a neuroimaging tool for diagnosing and monitoring Multiple System Atrophy (MSA). Using advanced deep learning methods, the index accurately measures brain atrophy in MSA patients over a year, correlating with disease severity. This breakthrough offers a more precise approach to tracking MSA progression and evaluating potential therapies. The MSA-AI’s objective measurement of brain volume changes could revolutionize MSA diagnosis and treatment monitoring, enhancing personalized care and clinical trial participant selection. The full publication can be accessed on Alterity’s website.

Read more at GlobeNewswire: Alterity Therapeutics Announces Publication on Novel MRI